The effect of a selective 5-lipoxygenase inhibitor, zileuton, on tissue damage in acute colonic inflammation in rats

被引:6
|
作者
Zarif, A
Eiznhamer, D
Callaghan, C
Doria, MI
Broutman, L
Keshavarzian, A
机构
[1] LOYOLA UNIV,MED CTR,DIV DIGEST DIS & NUTR,SCH MED,DEPT MED,MAYWOOD,IL 60153
[2] LOYOLA UNIV,SCH MED,DEPT PHARMACOL,MAYWOOD,IL 60153
[3] LOYOLA UNIV,SCH MED,DEPT PATHOL,MAYWOOD,IL 60153
[4] ABBOTT LABS,ABBOTT PK,IL 60064
[5] HINES VIRGINIA,MED SERV,HINES,IL
[6] HINES VIRGINIA,RES SERV,HINES,IL
关键词
D O I
10.1007/BF01488200
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Though the mechanism of tissue damage induced by colonic inflammation in ulcerative colitis is unknown, it has been established that the inflammatory mediator and potent neutrophil (PMN) chemotaxin, leukotriene B4(LTB(4)), is present in elevated amounts in the inflamed mucosa. The unique role of 5-lipoxygenase in the production of leukotrienes has made it a target for inhibition. This study used a rat model of acute colonic inflammation induced by a single IP injection of Mitomycin-C to test the efficacy of a specific and potent 5-lipoxygenase inhibitor zileuton in the treatment of colonic inflammation. We hypothesized that after inducing colitis in rats with mitomycin-C, the administration of oral zileuton would inhibit leukotriene production, thus preventing PMN infiltration and subsequent tissue damage. Zileuton decreased colonic tissue damage as measured by Histological score. However, zileuton did not significantly decrease neutrophil infiltration measured by mucosal PMN or myeloperoxidase (MPO) levels. Although zileuton was successful in significantly decreasing the frequency of severe colitis in our model, the fact that the decrease in PMN count and MPO Level was not statistically significant suggests that another mechanism may be involved in its anti-inflammatory effect.
引用
收藏
页码:217 / 227
页数:11
相关论文
共 50 条
  • [21] Reduction of the multiple organ injury and dysfunction caused by endotoxemia in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton
    Collin, M
    Rossi, A
    Cuzzocrea, S
    Patel, NSA
    Di Paola, R
    Hadley, J
    Collino, M
    Sautebin, L
    Thiemermann, C
    JOURNAL OF LEUKOCYTE BIOLOGY, 2004, 76 (05) : 961 - 970
  • [22] Intracolonic administration of zileuton, a selective 5-lipoxygenase inhibitor, accelerates healing in a rat model of chronic colitis
    Bertran, X
    Mane, J
    FernandezBanares, F
    Castella, E
    Bartoli, R
    Ojanguren, I
    Esteve, M
    Gassull, MA
    GUT, 1996, 38 (06) : 899 - 904
  • [23] PHARMACOKINETICS OF THE 5-LIPOXYGENASE INHIBITOR ZILEUTON IN SUBJECTS WITH VARIOUS DEGREES OF HEPATIC IMPAIRMENT
    BRAECKMAN, RA
    HUI, J
    CAVANAUGH, JH
    RUBIN, PD
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (02) : 181 - 181
  • [24] THE IMMUNOSUPPRESSIVE EFFECT OF 5-LIPOXYGENASE INHIBITOR ON LIVER ALLOTRANSPLANTATION IN RATS
    IYOBE, T
    IZUMI, R
    SHIMIZU, K
    TRANSPLANTATION, 1993, 56 (03) : 518 - 523
  • [25] THE EFFECT OF INHIBITION OF 5-LIPOXYGENASE BY ZILEUTON IN MILD-TO-MODERATE ASTHMA
    ISRAEL, E
    RUBIN, P
    KEMP, JP
    GROSSMAN, J
    PIERSON, W
    SIEGEL, SC
    TINKELMAN, D
    MURRAY, JJ
    BUSSE, W
    SEGAL, AT
    FISH, J
    KAISER, HB
    LEDFORD, D
    WENZEL, S
    ROSENTHAL, R
    COHN, J
    LANNI, C
    PEARLMAN, H
    KARAHALIOS, P
    DRAZEN, JM
    ANNALS OF INTERNAL MEDICINE, 1993, 119 (11) : 1059 - 1066
  • [26] A PILOT-STUDY OF ZILEUTON, A NOVEL SELECTIVE 5-LIPOXYGENASE INHIBITOR, IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS
    HACKSHAW, KV
    SHI, YH
    BRANDWEIN, SR
    JONES, K
    WESTCOTT, JY
    JOURNAL OF RHEUMATOLOGY, 1995, 22 (03) : 462 - 468
  • [27] Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton
    Rao, Navin L.
    Dunford, Paul J.
    Xue, Xiaohua
    Jiang, Xiaohui
    Lundeen, Katherine A.
    Coles, Fawn
    Riley, Jason P.
    Williams, Kacy N.
    Grice, Cheryl A.
    Edwards, James P.
    Karlsson, Lars
    Fourie, Anne M.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 321 (03): : 1154 - 1160
  • [28] Peroxynitrite-induced nitrotyrosination of proteins is blocked by direct 5-lipoxygenase inhibitor zileuton
    Coffey, MJ
    Phare, SM
    Peters-Golden, M
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2001, 299 (01): : 198 - 203
  • [29] MO ab initio study of the structural and electronic properties of the 5-lipoxygenase inhibitor zileuton
    Ramusino, MC
    THEOCHEM-JOURNAL OF MOLECULAR STRUCTURE, 1998, 427 : 237 - 242
  • [30] EFFICACY OF ZILEUTON, A 5-LIPOXYGENASE INHIBITOR, IN THE MAINTENANCE OF REMISSION IN PATIENTS WITH ULCERATIVE-COLITIS
    HAWKEY, C
    GASSULL, M
    LAURITSEN, K
    MARTIN, F
    OMORAIN, C
    RASKMADSEN, J
    WRIGHT, J
    DUBE, L
    ROUNTREE, L
    BROUTMAN, L
    GASTROENTEROLOGY, 1994, 106 (04) : A697 - A697